TW
Therapeutic Areas
Lion TCR Pipeline
| Drug | Indication | Phase |
|---|---|---|
| LioCyx‑M (LTCR‑H3‑4) | Advanced primary HBV‑related HCC | Phase 1b/2 |
| LTCR‑H3‑3 | Biomarker study for advanced primary HBV‑HCC | Phase 1 |
| LTCR‑H1‑1 | Prevention of HCC recurrence post‑liver transplantation | Phase 1 |
| LTCR‑H2‑1 | Treatment of HCC recurrence post‑liver transplantation | Pre‑clinical |
| LTCR‑H3‑1 | Advanced primary HBV‑HCC | Pre‑clinical |
| LTCR‑C2‑1 | Chronic HBV infection | Pre‑clinical |
| LTCR‑N1‑1 | EBV‑related nasopharyngeal carcinoma | Pre‑clinical |
| LTCR‑O1‑1 | Post‑transplant lymphoproliferative disorders | Pre‑clinical |